Beigene Ltd (BGNE) Stock Price Down 4.2%
Beigene Ltd (NASDAQ:BGNE) shares were down 4.2% on Friday . The stock traded as low as $26.24 and last traded at $26.24, with a volume of 62,904 shares traded. The stock had previously closed at $27.40.
Several research analysts recently weighed in on BGNE shares. Cowen and Company restated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. Morgan Stanley upped their price objective on shares of Beigene from $39.00 to $42.00 in a research report on Friday, April 8th. Finally, Zacks Investment Research upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $39.67.
The company’s 50-day moving average price is $29.15 and its 200 day moving average price is $28.87. The firm’s market cap is $593.50 million.
Beigene (NASDAQ:BGNE) last announced its earnings results on Wednesday, May 11th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.92. The business earned $0.70 million during the quarter. Beigene’s revenue was down 50.0% compared to the same quarter last year. On average, equities analysts predict that Beigene Ltd will post ($3.17) EPS for the current fiscal year.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.